Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Acta Diabetol. 2018 Jun;55(6):603-612. doi: 10.1007/s00592-018-1133-z. Epub 2018 Mar 24.
To define the contribution of chronic kidney disease (CKD) to excess mortality in patients with type 2 diabetes and identify the baseline variables associated with all-cause death in those with and without CKD using the RECursive Partitioning and Amalgamation (RECPAM) method.
This observational, longitudinal, cohort study enrolled 15,773 consecutive non-dialytic patients with type 2 diabetes in 19 Diabetes Clinics throughout Italy in 2006-2008. Based on the presence of albuminuria ≥ 30 mg day and/or estimated glomerular filtration rate (eGFR) < 60 mL min·1.73 m at baseline, patients were classified as having or not CKD. Vital status was verified on October 31, 2015 for 99.26% of patients.
Mortality increased with increasing albuminuria and eGFR category. Excess risk versus the general population was maximal in patients aged < 55 years in the worse albuminuria or eGFR category. Conversely, in subjects aged ≥ 75 years with albuminuria < 10 mg day or eGFR ≥ 75 mL min·1.73 m, excess mortality was no longer detectable. At RECPAM analysis, the main correlates of death in the whole cohort were albuminuria > 44 mg day, prevalent CVD, and eGFR < ~ 75 mL min·1.73 m; gender, prevalent CVD, and higher albuminuria in the normoalbuminuric range, in patients without CKD; and CVD, eGFR ~ < 50 mL min·1.73 m, and albuminuria > 53 mg day, in those with CKD.
CKD is a major contributor to excess mortality in type 2 diabetes, conferring a very high risk in younger patients and fully accounting for excess risk in the older ones. Higher albuminuria and lower eGFR, even in the normal range, identify individuals with increased mortality risk. Trial registration ClinicalTrials.gov (NCT00715481; https://clinicaltrials.gov/ct2/show/NCT00715481 ).
定义慢性肾脏病 (CKD) 对 2 型糖尿病患者死亡的影响,并使用递归分区和合并 (RECPAM) 方法确定伴有和不伴有 CKD 的患者全因死亡的基线变量。
这项观察性、纵向、队列研究纳入了 2006 年至 2008 年在意大利 19 个糖尿病诊所连续就诊的 15773 例非透析的 2 型糖尿病患者。根据基线时白蛋白尿≥30mg/d 和/或估算肾小球滤过率(eGFR)<60mL/min·1.73m,将患者分为有或无 CKD。截至 2015 年 10 月 31 日,99.26%的患者的生存状态得到了验证。
随着白蛋白尿和 eGFR 类别增加,死亡率增加。与一般人群相比,<55 岁且白蛋白尿或 eGFR 较差的患者的风险最高。相反,年龄≥75 岁且白蛋白尿<10mg/d 或 eGFR≥75mL/min·1.73m 的患者,已无法检测到超额死亡率。在 RECPAM 分析中,整个队列死亡的主要相关因素为白蛋白尿>44mg/d、既往心血管疾病 (CVD) 和 eGFR<~75mL/min·1.73m;在无 CKD 的患者中,为性别、既往 CVD 和正常白蛋白尿范围内更高的白蛋白尿;在有 CKD 的患者中,为 CVD、eGFR~<50mL/min·1.73m 和白蛋白尿>53mg/d。
CKD 是 2 型糖尿病患者死亡的主要原因,在年轻患者中风险极高,在老年患者中完全解释了超额风险。更高的白蛋白尿和更低的 eGFR,即使在正常范围内,也能识别出死亡风险增加的个体。
ClinicalTrials.gov(NCT00715481;https://clinicaltrials.gov/ct2/show/NCT00715481)。